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Abstract
Background: A rotator cuff tear is a common disabling shoulder problem. Symptoms include pain, weakness,
lack of shoulder mobility and sleep disturbance. Many patients require surgery to repair the tear; however,
there is a high failure rate. There is a pressing need to improve the outcome of rotator cuff surgery and the
use of patch augmentation to provide support to the healing process and improve patient outcomes holds
new promise. Patches have been made using different materials (e.g. human/animal skin or intestine tissue,
and completely synthetic materials) and processes (e.g. woven or a mesh). However, clinical evidence on their
use is limited. The aim of the patch-augmented rotator cuff surgery (PARCS) feasibility study is to determine,
using a mixed method approach, the design of a definitive randomised trial assessing the effectiveness and
cost-effectiveness of a patch to augment surgical repair of the rotator cuff that is both acceptable to
stakeholders and feasible.
Methods: The objectives of this six-stage mixed methods feasibility study are to determine current practice, evidence
and views about patch use; achieve consensus on the design of a randomised trial to evaluate patch-augmented rotator
cuff surgery; and assess the acceptability and feasibility of the proposed design. The six stages will involve a systematic
review of clinical evidence, two surveys of surgeons, focus groups and interviews with stakeholders, a Delphi study and a
consensus meeting. The various stakeholders (including patients, surgeons, and representatives from industry, the NHS
and regulatory bodies) will be involved across the six stages.
Discussion: The PARCS feasibility study will inform the feasibility and acceptability of a randomised trial of the
effectiveness and cost-effectiveness of a patch-augmented rotator cuff surgery. Consensus opinion on the basic design of
a randomised trial will be sought.
Trial registration: Not applicable.
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Background
Clinical problem
Rotator cuff conditions relate to the tendons and mus-
cles surrounding the shoulder joint. They account for up
to 70% of shoulder pain problems and are the third most
prevalent musculoskeletal disorder after lower back and
neck pain [1, 2]. A severe but common rotator cuff
problem is a rotator cuff tendon tear. Symptoms include
pain, weakness, lack of shoulder mobility and sleep dis-
turbance. Initial management is conservative and in-
cludes rest with simple pain management through
paracetamol and non-steroidal anti-inflammatory drugs,
often followed by an injection of corticosteroid into the
subacromial space between the acromion process of the
shoulder blade and the rotator cuff tendons below [3].
Physiotherapy involving strengthening and stretching ex-
ercises may also be used [4]. Approximately 40% of pa-
tients will continue to experience pain despite
conservative management [5, 6], and many will require
surgery to repair a tear in the rotator cuff.
Surgery for rotator cuff repair
Surgical repair of the rotator cuff seeks to attach the tendon
to the bone to allow the tear to heal and improve patient out-
comes. Around 9000 rotator cuff repairs are performed each
year in the NHS in England, at a cost of £6628 per operation
(£60 million per year), and this number is continuing to grow
[2, 7]. There is substantial variation in surgical practice, which
includes the type of surgery (open or arthroscopic), surgical
techniques (for example the use of anchors and type of su-
ture), and type and duration of ancillary conservative treat-
ment (including corticosteroid injections, physiotherapy, rest,
advice and analgesia) [8]. Rotator cuff surgery can have mixed
outcomes for patients [2]. It has a high failure rate (25–50%
[9–11] within 12 months) and is expensive, invasive and in-
convenient to patients. Re-operation is also sometimes neces-
sary. Although there are different views about the key drivers
of the health outcome, a number of factors are consistently re-
lated to poor outcomes, particularly increasing age and in-
creasing tear size [12]. Four of the top 10 treatment
uncertainties for common shoulder problems from a priority
setting partnership for surgery for common shoulder prob-
lems’ involving patients, carers and clinicians [13] concerned
rotator cuff tears. There is, therefore, a pressing need to pro-
gress surgical options for rotator cuff repairs and to improve
tendon healing and outcomes for patients [14].
A number of unsuccessful surgical approaches have
been tried to improve the outcome of rotator cuff repair
[2, 11, 15, 16]. The United Kingdom Rotator Cuff Trial
(UKUFF) trial found that minimally invasive (arthro-
scopic) surgery had no extra benefit over open surgery
[17]. An updated systematic search revealed six more tri-
als comparing two surgical interventions [18–23]. These
RCTs were single centre and were relatively small and
mainly included participants with full thickness rotator
cuff tears and with small and medium rotator cuff tears.
One further ongoing study was identified [24]. There was
no evidence that the use of suture anchors or alternate
methods of suturing improve healing rates. Attention
has recently focused on improving the biology of the
torn tendon at the time of surgery and for the critical
8–12-week period after surgery, when effective healing
is needed [25]. Repairs commonly fail due to poor tis-
sue and bone quality or inadequate fixing of the ten-
don to the bone, allowing the tendon to pull away
from the bone.
Patch-augmented rotator cuff surgery
A promising, under-evaluated area for further assess-
ment is the use of a patch to provide a support structure
or ‘scaffold’ for the repair, to improve the fixing of the
tendon to the bone and tendon healing [26, 27]. These
implants are also referred to as an extracellular or acel-
lular matrix (when made from human or animal cells) or
as a graft (e.g. an allograft, autograft or xenograft, de-
pending on the source material used to manufacture the
patch). The patch is surgically sutured on top of the
tendon-to-bone repair to strengthen the repair and aid
tendon healing, thereby reducing the likelihood of failure
and improving patient outcomes. [28]
Patches have been made using different materials (hu-
man/animal heart, skin or intestine tissue, and com-
pletely synthetic materials) and processes (e.g. woven or
mesh approaches) and to different sizes. They can be de-
signed to be absorbable, avoiding the possibility of later
surgical complications or surgical removal. [29] Patches
differ in how they respond to tendon tissue and their
mechanical properties. [30] Some have been designed
specifically or can be tailored in size and shape for spe-
cific use in rotator cuff surgery, whereas others have
been developed for other soft-tissue contexts (e.g. anter-
ior cruciate ligament reconstruction in the knee or for
hernia repair). Recent advances include the development
of electrospun materials [31] and exploration of the con-
current use of growth factors. Electrospun materials
have a structure that closely resembles the surrounding
tissue; they provide biological cues to encourage cell
growth and tissue healing. The aim of these and other
biomimetic materials is to avoid adverse immunological
responses, which some tissue-based patches have pro-
voked [32]. Augmenting surgical repair with a patch
may also enable the repair of tears that are currently
considered unrepairable [26, 29, 31, 33, 34]. A number
of patches have received regulatory approval in the USA
and/or by an EU-notified body for use in surgical repair
of the rotator cuff. There are more patches in develop-
ment. There is currently a window of opportunity to de-
sign, gain stakeholder buy-in for, and conduct a timely
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randomised controlled trial (RCT) before widespread
adoption of these medical devices for rotator cuff sur-
gery. However, the design and feasibility of such a trial is
not clear. Key uncertainties about the design and con-
duct of such a trial include the types of patches that are
in clinical use in the NHS, which should be evaluated in
a trial, which patients would benefit most, how the sur-
gery should be delivered and which outcomes should be
measured.
Study design
Aim and objectives
The aim of this study (PARCS) is to determine the de-
sign of a definitive randomised trial assessing the effect-
iveness and cost-effectiveness of a patch to augment
surgical repair of the rotator cuff tendon that is both ac-
ceptable and feasible.
The specific objectives are to:
1. Review existing evidence to identify candidate
patches for use in a randomised trial and the
evidence relating to their clinical use,
2. Determine current practice in the NHS relating to
the use of patches to augment rotator cuff repair,
3. Assess the acceptability of a trial assessing patch
augmented rotator cuff repair to patients and surgeons,
4. Assess the feasibility of a trial of patch-augmented
rotator cuff repair,
5. Achieve consensus on the key elements of the
design of a definitive randomised trial to assess the
use of patches to augment rotator cuff repair,
6. Confirm the scope of the health economic
evaluation required in the trial to appropriately
assess its cost-effectiveness,
7. Identify areas for further relevant research related
to patch-augmented rotator cuff surgery.
PARCS is a mixed methods feasibility study consisting of six
stages. The design of each stage is given below. As this proto-
col pertains to stages 2–6 only, a very brief summary of stage
1 is provided. The consensus methods approach adopted
builds on the work by the IDEAL Collaboration for evaluating
surgical innovation and devices in early-stage and randomised
trial assessments [35] and adapts the methodology used for
achieving expert consensus in guideline development and de-
velopment of core outcome sets [36–38] to the broader scope
of trial design, see Fig. 1 for a summary flow diagram.
Stage 1: Systematic review of candidate patches and
related clinical evidence
A systematic review of the surgical management of rota-
tor cuff repair with augmentative patch will be per-
formed. This protocol is available elsewhere [39].
Stages 2 and 3: Surveys of surgical practice, acceptability
and feasibility of a randomised trial
The main objective of the two surveys together is to as-
certain current NHS clinical practice relating to the use
of patches to augment rotator cuff repair and practical
issues related to conduct of a trial in this area.
British Elbow and Shoulder Society (BESS) membership
survey (stage 2)
The aim of this survey is to identify current UK clinical
practice and gather information on surgeon opinion re-
lating to the factors that influence their choice of patch
and patient suitability. This survey will also explore the
interest in participating in a RCT of patch augmented
rotator cuff repair. An invite to participate in this online
survey will be sent to all surgeon members of the British
Elbow and Shoulder Society (BESS). The main mechan-
ism of approaching potential participants will be via the
BESS society email list; the invite will be sent out by the
BESS office to avoid unnecessary sharing of personal
data with the PARCS team. Information about the study
and a hyperlink to the relevant survey will be provided.
Reminder emails will be sent to the entire sample in a
similar manner. The survey will be delivered online
using the Bristol Online Survey (BOS) tool or an equiva-
lent system [40]. Surgeon members of BESS attending
the 2017 annual meeting will be offered an opportunity
to complete the survey during the meeting. A member
of the PARCS study team will provide verbal and, where
appropriate, written study information. If the surgeon is
agreeable, they will be given access to the online survey
for completion at the meeting. Prior to finalising, the
survey will be piloted internally amongst the study inves-
tigators and a number of external individuals as appro-
priate. The survey is anticipated to take approximately
10 min to complete and is available in Additional file 1.
The BESS membership includes approximately 350 clin-
ically active shoulder surgeons. There is no minimum
number of responses required. The response rate will be
defined as the number of responding participants di-
vided by the number of eligible people invited. The stat-
istical analysis will be descriptive only. Responses will be
summarised quantitatively or narratively, as appropriate
(e.g. using Microsoft Excel and/or Stata).
Survey of shoulder surgeon trialists (stage 3)
The second survey will build upon the findings of the
first survey and will be for a subset of surgeons who
have previously been actively involved in previous UK
shoulder surgery trials as study investigators. The sur-
veys will also partly address trial acceptability and feasi-
bility (patient population, surgical procedures and
practical recruitment process considerations) from the
surgeon perspective. It will be directed at surgeons who
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are trial active and, therefore, most likely to participate
in a randomised controlled trial of patch-augmented ro-
tator cuff surgery. A network of surgeon trialists who
have participated in previous NHS-based shoulder surgi-
cal trials will be invited to take part. This will include
surgeons who acted as principal investigator for the
UKUFF, CSAW and UKFroST trials [2, 41, 42]. At least
30 research active orthopaedic shoulder surgeons will be
invited to take part. This is considered large enough to
meet the aim of this component of the project and en-
sure that a range of surgeons and centres are included.
To be eligible, an individual will need to be a practicing
orthopaedic shoulder surgeon who is currently, or has
previously been, an investigator for a RCT of shoulder
surgery, i.e. experienced in recruitment, trial treatments
and completion of case report forms. Eligible
participants will be identified by the PARCS Study Man-
agement Group based upon the advice of the trial man-
agers of the aforementioned shoulder surgery trials. The
PARCS Study Management Group includes individuals
who were involved in all of these trials. They will be re-
cruited through a personalised, email or face-to-face in-
vitation. These surgeons will be invited based on their
previous experience in shoulder surgical trials. Email
correspondence (invites/reminders where needed) will
be personalised. During the survey, participants will be
asked to register their interest in taking part in further
stages of the PARCS study. The number of responses
and feedback received on completing the stage 2 survey
will be taken into account when finalising the stage 3
survey (see Additional file 2). This survey is anticipated
to approximately 15 min to complete. There is no
Fig. 1 Study flow chart. Patch-augmented rotator cuff repair study (PARCS)
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minimum number of responses required. The survey
data will be analysed in a similar manner to the stage 3
survey.
Stage 4: Focus groups
Focus groups allow participants to speak freely about
their concerns and offer their views about the existing
and proposed evaluation of a new approach to surgical
treatment. They are particularly useful for helping to
identify issues that resonate with lay people and the pub-
lic at large in matters of healthcare [43, 44]. Focus
groups are widely used in health services research.
Using a number of focus groups, we aim to access a
broad range of stakeholder views and opinions on the
acceptability of the use of patches in the augmentation
of rotator cuff repair and the trial design options that
may be used to test them. Themes and issues identified
from the surgeon survey (stages 2 and 3) will help to
form topics for discussion if findings are available when
this stage is ongoing.
Members will be recruited to separate focus groups,
each reflecting the various key stakeholders:
A. Patients/public (including carers) with current or
previous rotator cuff or other shoulder problems.
This included but was not limited to those who had
undergone rotator cuff surgery
 Two focus groups will be conducted, one each in
two regions of England (Thames Valley in the
south and Tees Valley in the north)
B. Representatives from Industry
C. Other stakeholder representatives, including
regulatory bodies, commissioners and the NHS
such as those involved in research delivery and
procurement of surgical equipment
Group A is considered to be the key stakeholder
group. However, the introduction of patches into the
NHS has regulatory and cost implications; therefore, it is
relevant to include the views and opinions of groups B
and C in the study. Potential participants will be invited
and recruited using various avenues.
Consultant orthopaedic surgeons (and PARCS Study
Management Group members) based at the Nuffield
Orthopaedic Centre, Oxford and the James Cook Uni-
versity Hospital, South Tees, will approach potential pa-
tient participants though outpatient and physiotherapy
clinics. Study staff may also contact patients previously
known to study clinical investigators at the two sites. If
patient/public uptake is low, poster advertisement in the
local community may also be used, and if necessary, the
geographical area extended. Local or national websites
set up to increase public and patient involvement in
clinical research may also be utilised. Other stakeholders
and individuals with relevant experience and knowledge
will be identified, approached and invited to participate
directly. This may be through professional or personal
acquaintance. If necessary, the technique of snowballing
may be utilised, i.e. respondents may be asked to pass
on information to other potential participants [45]. A
balance of men and women within each focus group will
be aimed for.
Each focus group will aim to involve four to eight par-
ticipants and will be held at the Botnar Research Centre,
University of Oxford (Oxford, Thames Valley, UK), the
South Tees Institute of Learning, Research and
Innovation (Middlesbrough, Tees Valley, UK), or where
possible, at a location better suited to participants (e.g.
their place of work or by teleconference). Focus groups
sessions will last for a maximum of 2 h. There will be
breaks of at least 15 min per hour of discussion. Refresh-
ments will be provided during the focus group session.
Focus groups will be facilitated by a trained member
of the PARCS study team. Discussions will be audio re-
corded, and one or two observers will take notes to aid
in the transcription of audio files and analysis. Partici-
pants will provide their written consent prior to audio
recording. Any identifying information appearing in
focus group transcripts will be replaced with a pseudo-
nym as soon as possible following transcription to min-
imise risk of participant identification.
Ahead of the focus group session, potential partici-
pants will be provided with a study information sheet
(specifically tailored to their stakeholder group) that de-
scribes the aim of the focus group, what taking part will
involve and the consent procedure. Depending on indi-
vidual preference, this information will be supplied by
hand, email or post. Written informed consent will be
obtained. As soon as they are confirmed, arrangements
for the focus group (date, time and location) will be
provided.
During the focus group session, the aim of the focus
group and the PARCS project will be briefly introduced
and participants will be asked to consider a number of
relevant issues, scenarios or vignettes. Key items of in-
formation about the possible trial design options, such
as the different kinds of patches available, the choice of
study arms, most appropriate outcome measures and
methods of data collection (e.g. biopsy, patient question-
naires, site visits), will be raised. The way in which this
information is delivered, and the level of detail consid-
ered, will likely be adapted according to participant
group.
Participants of the patient/public focus groups will be
asked to provide some basic background information
about themselves (gender, age, relevant experience and
previous treatments). To ensure anonymity, participants
will be provided with a plain opaque envelope in which
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to place the completed ‘background information form’
and will be instructed to place the envelope in a box as
they leave.
If it is not feasible to conduct a focus group meeting, or
for all individuals to make the same date and location, po-
tential participants may be offered an individual or, as a
subset of all participants, a separate face-to-face or tele-
phone interview instead. Participants will have the right to
leave requests for information unanswered if they wish.
We will reassure these participants and inform them that
there will be no adverse consequences from this and are
free to withdraw themselves at any time.
Data collected at the focus groups (stage 4) will be
analysed alongside data collection using thematic ana-
lysis [46]. The emphasis of the analysis will be on the ac-
ceptability of the proposed trial and on factors that
might facilitate or impede such acceptability. Thematic
content analysis will be carried out by three members of
the PARCS study team (CC, NM JCC) and will consist
of the following steps:
(1) Familiarisation with the focus group transcript,
(2) Coding the transcript text under relevant themes,
(3) Agreeing a thematic framework,
(4) Applying the framework to subsequent focus group
transcripts,
(5) Interpreting and summarising the data within each
theme,
(6) Drawing out implications for trial design and stages
5 to 6 of the feasibility study (JAC will also be
involved in this step).
Coding will be both deductive (guided by the themes
included in the focus group topic guides) and inductive
(allowing the emergence of unanticipated themes and
sub-themes). Steps 3 and 4 will be iterative, i.e. the the-
matic framework may be refined or modified and re-
applied to transcripts as the analysis progresses. Changes
to the thematic framework will require agreement of all
members involved in steps 1–5.
Stage 5: Delphi study
A Delphi study to develop a consensus on the best way
to design a clinical trial of patch-augmented rotator cuff
surgery will be conducted. The Delphi method is a
structured process of obtaining information from a
group of experts using a series of related questionnaires,
each one refined using respondents’ feedback from a
previous version [47]. Delphi is a well-known and in-
creasingly common method used in the clinical setting
to establish a consensus [43, 47, 48]. A multi-stage on-
line Delphi survey consisting of at least two but no more
than three rounds will be conducted. The survey will be
developed and conducted using the BOS System or an
equivalent [40].
Participants involved in stages 2 to 4 of the PARCS
Study will be invited to take part in stage 5 according to
stakeholder group and background. Given the nature of
the study, there has been no formal sample size calcula-
tion but around 50–80 are anticipated. There are gener-
ally no accepted guidelines for the optimal sample size
needed to achieve consensus in a Delphi studies [49].
This sample size was based on previous experience of
conducting this type of survey and anticipated attrition
rates at each round. Substantial loss from the initial to
final round is not unusual [48, 50].
Where appropriate, stakeholders who have relevant
experience but did not take part in previous stages may
be invited to participate. These potential participants will
be identified and recruited using a similar approach as
described in stages 3 and 4. Electronic confirmation of
consent will be obtained.
Delphi study participants will have their name and
contact email address entered in to the suryey system
[40]. An email will be sent to each participant containing
a personalised link that enables access for survey com-
pletion. Findings from stages 1 to 4 will determine the
design elements to be included in the first round of the
Delphi survey. Two versions of the survey will be used
one for patient and public stakeholders and one for pro-
fessional (e.g. surgeons, researchers) stakeholders. The
former version will have a subset of the full set of ques-
tion which are most pertinent to this stakeholder group
and will be presented using more accessible language
and avoiding as far as possible technical terminology.
During completion of the first round, survey partici-
pants will be asked to supply some basic demographic
information (for example, age, background, current em-
ployment and position (professionals only), relevant
medical history (patients/public) and number of years of
relevant experience) and will be allocated a unique iden-
tifier used for administrative and data analysis purposes.
Participants will be presented in the survey with pro-
posed elements (e.g. choice of two or three arm trial de-
sign, eligibility criteria for participation and information
on the timing of the outcome data collection) of the trial
design and asked to score agreement with each design
element using a 1–5 scale, where 1 represents complete
disagreement and 5 represents complete agreement. Par-
ticipants will be given the opportunity to communicate
their personal suggestions with regards to changes to a
design element or any additional design elements they
feel should be included in future rounds in order to
achieve consensus. All initial design elements will be
carried forward to subsequent rounds of the Delphi sur-
vey though the content will be adaptable dependent
upon the response received. New design elements
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suggested by participants in round one of the Delphi
survey will be reviewed at least two members of the
PARCS study team. The wider project team will be con-
sulted if there is any uncertainty or to decide if an add-
itional element should be added.
Participants will receive a summary of the findings
from the previous round in subsequent rounds. They
will be asked to reflect on their own responses and also
the collated responses. Participants will then score each
design element. The final set of proposals, areas of
provisional consensus and remaining disagreement and
uncertainty will then be brought forward to the consen-
sus meeting in stage 6 and used as the basis for
discussion.
Where necessary, at each round of this Delphi survey,
non-responders will receive a maximum of two reminder
messages. The final reminder will contain a specific
deadline for survey closure [51]. Each survey will take
approximately 20 min to complete.
Scores (range 1–5) from each round will be calculated
as a percentage of the total responses. We will define
consensus for the content of the design elements pro-
posal as > 70% of responses rating the element 4 or
greater and not more than 15% of responses rating the
element 1. Median and ranges will also be produced for
the scores. We will explore similarities and differences
across stakeholder groups. Textual responses will be
summarised narratively.
Stage 6: Consensus meeting
Findings from stages 1–5 will feed into, and inform the
structure of, a 2-day face-to-face meeting where the final
consensus on an acceptable and feasible trial design for
a definitive randomised trial to assess the effectiveness
and cost-effectiveness of a patch to augment surgical re-
pair of the rotator cuff tendon will be sought. This meet-
ing will involve a range of stakeholders (including
patient and public representatives, surgeons and trialists
who took part in stages 2–5 of the study). Participants
will be selected for invite based on their perspectives, ex-
perience and background. This will be done in order to
ensure a range of stakeholder groups are represented
and individuals from different backgrounds and experi-
ences (e.g. surgeons who do currently use patches to
augment rotator cuff repair along with those who would
be potentially willing to do so for a trial). To ensure a
robust decision is made, approximately 30 stakeholders
will take part in this meeting.
Ahead of the consensus meeting, participants will be
sent a summary of findings from earlier stages of the
project. Patient and public representatives will be reim-
bursed for expenses and compensated for their time in
line with current NIHR INVOLVE guidelines on pay-
ment and recognition for public involvement [52]. The
meeting will be structured to ensure key areas of uncer-
tainty and/or disagreement are identified. Consensus on
key elements of the trial design: patient eligibility, inter-
vention and control definitions, surgeon requirements,
outcomes and target difference will be sought. Draft
guidance, options and recommendations for a rando-
mised trial assessing patch-augmented rotator cuff sur-
gery will be developed from previous work updated in
light of the findings from previous stages.
A post-meeting report will be drafted and circulated to
participants for their review and comments. The report
will detail the key design decisions and will be divided
into sections on methods, study design issues (e.g. the
definition of comparison groups) and special topics (e.g.
allowable variation in surgical technique).
Project management and adherence to regulatory
requirements
The investigators will ensure that this study is conducted
in accordance with relevant regulations and with the
Good Clinical Practice. The study will be conducted in
accordance with the current approved protocol, relevant
regulations and standard operating procedures. The in-
dependent Study Steering Committee (SSC) will oversee
study conduct and progress. A potential participant will
be allowed as much time as they wish (within the con-
straints of the project timelines) to consider the infor-
mation, and the opportunity to ask questions. At all
stages of the study, it will be clearly stated that a partici-
pant is free to withdraw themselves and/or their re-
sponse data at any time where it can be identified and
removed (this is not likely to be feasible for responses to
stages 4–6). There will be no adverse consequences or
impacts on future care if this is done.
The study will comply with the Data Protection Act,
which requires data to be anonymised as soon as it is
practical to do so. Following publication of our findings,
anonymised individual participant data (as far as is feas-
ible according to the nature of the data) will be perman-
ently archived. Anonymised data may be shared with
legitimate internal and external researchers. The chief
investigator will act as the data custodian for this study.
The investigators will also ensure that this study is
conducted in accordance with the principles of the Dec-
laration of Helsinki.
Progress to date
The stage 2 and 3 surveys have now been completed,
and an initial summary of the findings produced. Focus
groups and interviews (stage 4) have now also been
completed, and a summary of findings of this stage pro-
duced. Stage 5 is in progress with a date set for the con-
sensus meeting (stage 6) in early 2019.
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Discussion
Rotator cuff tears are a relatively common problem, and
the number of operations to repair them is likely to
grow in developed countries over the foreseeable future
as the population ages. Despite benefits for many pa-
tients, the operation does not provide sustained benefit
for a substantial minority. The augmentation of the op-
eration with a patch seems promising with some evi-
dence of clinical benefit. However, which patients might
benefit most and the extent of such a benefit is unclear
particularly in what might be described as a typical pa-
tient. Furthermore, there is key uncertainty regarding
the available patches, the clinical evidence on their use
and the views of key stakeholders particularly patients
and surgeons on their use. When the prospect of con-
ducting a large multicentre randomised trial to evaluate
their use is considered, it is clear that a preparatory re-
search would be highly valuable to inform the design of
such a study and indeed if it is feasible to conduct. Fur-
thermore, various trial design options are possible and it
is not clear a priori which is most appropriate.
The main strengths of the study design are the
planned systematic involvement of a variety of different
stakeholder groups and the use of multiple quantitative
and qualitative methodologies, in order to seek to pro-
duce the most informed output from the study. The
main weaknesses of the study are the relatively slow and
more time-consuming nature of the overall study com-
pared to simpler feasibility study designs. Participants in
stages 2–6 may not be fully representative of all stake-
holders or reflect the full range of viewpoints and per-
spective. For example, surgeons who use patches in their
clinical practice may have been more likely to participate
in the stage 2 and 3 surveys. This could limit the
generalizability and applicability of the findings.
The PARCS feasibility study seeks to address this gap
in knowledge and seeks to take an inclusive approach
with a variety of research methodologies utilised to in-
form the feasibility and acceptability of a randomised
trial in this area. Specifically, one that would evaluate
the effectiveness and cost-effectiveness in the context of
the NHS in the UK is in mind. It is hoped that this study
might lead to the funding and conduct of such a study.
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